姓名： 谢国祥 职务： 职称： 特聘研究员 政治面貌： 中共党员 最高学历学位： 研究生，博士 专业: 分析化学 所属院系: 药学院 研究方向: 代谢组学新技术开发，新药靶点发现与转化 电话: 信箱: xieguoxiang@nbu.edu.cn 个人主页:

个人简介

宁波大学医学部特聘研究员。长期从事质谱代谢组学平台技术的研发、标准化及其在转化医学研究领域的应用。以第一及通讯作者在Cell Reports Medicine，Genome Medicine，EbioMedicine，BMC Medicine，Analytical Chemistry等杂志发表高水平论文50余篇；获得授权发明专利16项，软件著作权14项；主持深圳市科创委创新创业项目、深圳市工信局深圳市战略性新兴产业发展资金新兴产业扶持计划项目、企业横向课题多项，作为课题骨干参与国家重大科学研究计划项目（973计划）以及美国国立卫生研究院项目；获评深圳市海外高层次“孔雀计划”人才，获上海市科学技术奖二等奖、宁波市科学技术进步奖二等奖；担任World Journal of Diabetes，BMC Medicine，Journal of Translational Gastroenterology，Frontiers in Pharmacology等杂志副主编、编委；连续6年（2020-2025）入选爱思唯尔（Elsevier）与美国斯坦福大学（Stanford University）发布的“全球前2%顶尖科学家”榜单 (World's Top 2% Scientists）。

学习和工作经历

2026- 特聘研究员，宁波大学医学部

2018-2026  首席科学家，深圳市绘云生物科技有限公司

2013-2020  助理教授，夏威夷大学癌症中心

2011-2013  研究科学家，美国北卡罗来纳大学格林波诺转化生物医学研究中心

2009-2011   博士后研究员，美国北卡罗来纳大学格林波诺健康与人文学院

2007-2009  助理研究员，上海交通大学系统生物医学研究院

2004-2007 博士，药剂学，上海交通大学

2001-2004 硕士，应用化学，华东理工大学

1997-2001 学士，工业分析，江苏石油化工学院（现常州大学）

近年发表的主要论文

1 Chen YY^#, Yang TB^#, Chen TL, Xiao HM, Zhou KJ, Ding KK, Liu Q, Li MC, Peng XF, Sun T, Wang XN, Liu P, Deng X, Zhang ZH, Zhang K, Huang XZ, CHI XL, Kong AP, Wong VW*, Jia W*, Xie GX*. A metabolite-augmented FIB-4 machine learning panel achieves superior liver fibrosis staging in chronic liver disease. Cell Reports Medicine. 2026,

2 Mai Y^#, Huang F^#, MI H, Cao Z, Li Y, Zhou K, Liu J, Xie G*, Liao Wang*. Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer's disease and mild cognitive impairment. Neurotherapeutics. 2025. e00756.

3 Sun YM^#, Kuang J.L^#, Zhang HH, Xia XX, Wang JY, Zheng D, Zhou KJ, Tang YJ, Zhao AH, Jia W*, Xie GX*, Zheng XJ*. Pig bile powder maintains blood glucose homeostasis by promoting GLP-1 secretion via FXR. World Journal of Diabetes. 2025; 16(6): 103616

4 Wang JX^#, Liu XZ^#, GUO Z, Zhang HL, Qi L, Liu J, Liu P*, Xie GX*, Wang XN*. Differences in fatty acid metabolism between MCDD and HFD induced non-alcoholic fatty liver disease model mice. Biological Procedures Online. 2025; 27(1): 14.

5 Xie G.*, Zhou K., Sun W., Huang F., Wang L., Zhou Z., Jia W*. Analytical validation of a LC-MS/MS based in vitro diagnostic kit for the quantification of L-tyrosine and taurocholic acid for liver fibrosis diagnosis. Practical Laboratory Medicine, 2025, 44: e00454.

6 Hong Z^#, Zhou K^#, Wei Y, Ma B, Xie G*, Zhang Z*, Liang J*. Associations of Plasma and Fecal Metabolites with Body Mass Index and Body Fat Distribution in Children. The Journal of Clinical Endocrinology & Metabolism. 2025; 110(4): e1173-e1184.

7 Tang L. ^#, Ding K. ^#, Li M. ^#, Chao X., Sun T., Guo Y., Peng X., Jia W., Chen T.*, Xie G.*, Feng L*. Differences in oral microbiota associated with type 2 diabetes mellitus between the Dai and Han populations. Journal of Oral Microbiology, 2024, 17(1): 2442420.

8 Wu L^#, Wang J^#, Lei J, Ge K, Qu C, Liu J, Huang F, Sun D, Chao X, Chen TL, Zhao AH, Jia W, Zheng XJ*, Xie G*. Toxicological evaluation of porcine bile powder in Kunming mice and Sprague-Dawley rats. Frontiers in Pharmacology. 2024, 1424940, DOI: 10.3389/fphar.2024.1424940.

9 Liu, X., Wang, J., Li, M., Qiu, J., Li X, Qi L, Liu J, Liu P*, Xie G*, Wang XN*. Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis. Journal of Gastroenterology and Hepatology, 2023; 38(8):1438-1446.

10 Wang J, Zheng D, Huang F, Zhao A, Kuang J, Ren Z, Chen T, Lei J, Lin J, Wang X, Jia W, Xie G*, Zheng X*. Theabrownin and Poria cocos Polysaccharide Improve Lipid Metabolism via Modulation of Bile Acid and Fatty Acid Metabolism. Front Pharmacol. 2022;13:875549.

11 Chen T, Zhou K, Sun T, Sang C, Jia W*, Xie G*. Altered bile acid glycine: taurine ratio in the progression of chronic liver disease. Journal of Gastroenterology and Hepatology. 2022, 37(1): 208-215.

12 Xie G^#*, Wang L^#, Chen T^#, Zhou K^#, Zhang Z, Li J, Sun B, Guo Y, Wang X, Wang Y, Zhang H, Liu P, Nicholson JK, Ge W*, Jia W*. A Metabolite Array Technology for Precision Medicine. Analytical chemistry. 2021;93(14):5709-17. (ESI高被引论文)

13 Sang C, Wang X, Zhou K, Sun T, Bian H, Gao X, Wang Y, Zhang H, Jia W, Liu P, Xie G*, Chen T*. Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease. Journal of Proteome Research. 2021, 20(5): 2340-2351.

14 Xie G, Jiang R, Wang X, Liu P, Zhao A, Wu Y, Huang F, Liu Z, Rajani C, Zheng X, Qiu J, Zhang X, Zhao S, Bian H, Gao X, Sun B, Jia W*. Conjugated secondary 12 α -hydroxylated bile acids promote liver fibrogenesis. EbioMedicine. 2021, 66: 103290.

15 Sang C, Yan H, Chan WK, Zhu X, Sun T, Chang X, Xia M, Sun X, Hu X, Gao X, Jia W, Bian H, Chen T*, Xie G* Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. Front. Med. 2021, 8: 637652.

16 Qiu J, Yan J, Liu W, Du Z, Qi L, Liu J, Xie G*, Liu P*, Wang X*. Metabolomics Analysis Delineates the Therapeutic Effects of Huangqi Decoction and Astragalosides on α-naphthylisothiocyanate (ANIT)-Induced Cholestasis in Rats. Journal of Ethnopharmacology. 2021, 268: 113658.

17 Liang D, Liu Q, Zhou K, Jia W, Xie G*, Chen T*. IP4M: an integrated platform for mass spectrometry-based metabolomics data mining. BMC Bioinformatics. 2020;21(1): 444.

18 Xie, G., Wang, X., Wei, R. et al. Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection. BMC Med. 2020, 18: 144.

19 Xie G, Wang X, Jiang R, Zhao A, Yan J, Zheng X, Huang F, Liu X, Panee J, Rajani C, Yao C, Yu H, Jia W, Sun B, Liu P, Jia W*. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. EBioMedicine. 2018, 37: 294-306.

20 Xie G, Wang S, Zhang H, Zhao A, Liu J, Ma Y, Lan K, Ni Y, Liu C, Liu P. Poly‐Pharmacokinetic Study of a Multicomponent Herbal Medicine in Healthy Chinese Volunteers. Clin Pharmacol Ther. 2018, 103(4):692-702.

近年主持/参与的项目

1.国家自然科学基金委员会，面上项目，82471441，梭状芽孢杆菌代谢的猪去氧胆酸促进脑胆固醇清除缓解早发阿尔茨海默的作用机制，2025-01至2028-12，48万元，在研，项目参与人。

2.深圳市工业和信息化局, 产业链关键环节提升项目, 20200618130124293, 基于质谱的糖尿病检测系统的研发及应用, 2018-08 至 2020-12, 219万元, 结题, 主持。

3.深圳市科技创新委员会，肝病诊断试剂盒，项目批准号：深科技创新【2020】82号，80万元，结题，主持。

4.国家自然科学基金委员会，面上项目，31972935，基于代谢物组-微生物组深度关联分析策略的2型糖尿病进展模式和时间特异性关联对研究，2020-01至2023-12，56万元，结题，项目参与人。

5.国家自然科学基金委员会，面上项目，81774196，基于核受体FXR活化探讨茵陈蒿汤调控NAFLD胆汁淤积胆汁酸和脂肪代谢效应机制研究，2018.01-2021.12，53万元，结题，项目参与人。

已获授权的发明专利

1.胆红素含量检测方法及试剂盒。贾伟，谢国祥，周科军。中国发明专利，专利号 ZL2020 11506061.7

2.一种用于评估新生儿胆道闭锁风险的代谢物组合及其应用。贾伟，谢国祥，中国发明专利，专利号ZL202410642586.5

3.用于肝纤维化和肝硬化诊断的生物标志物和试剂盒及使用方法。贾伟，谢国祥，卫润民，王京晔，中国发明专利，专利号ZL201810769995.6

4.用于受试体检测非酒精性脂肪性肝病状态的诊断装置及计算机系统。贾伟，谢国祥，陈天璐，周科军，中国发明专利，专利号ZL 202110323130.9

5.用于评估受试者心血管疾病风险的代谢标志物组合及其应用，贾伟，谢国祥，林志龙。中国发明专利，专利号ZL202110000655.9

6.用于检测情感障碍的代谢标记物和试剂盒及使用方法。贾伟，谢国祥，中国发明专利，专利号ZL 202010658243.X

7.生物样品中多种代谢物定量检测方法及代谢芯片。贾伟，谢国祥，王鹭，中国发明专利，专利号ZL201811223486.X

8.胆汁酸衍生物及其组合物和应用。贾伟;谢国祥;翟宁;赵爱华;郑晓皎。中国发明专利，专利号：ZL 201910875185.3

著作编写

代谢组学与精准医学，编委，上海交通大学出版社，2017年，ISBN 9787313184009

医学代谢组学，编委，上海科学技术出版社，2011年，ISBN 978-7-5478-0492-6

Metabonomics and Gut Microbiota in Nutrition and Disease. Springer. 2015. ISBN 978-1-4471-6539-2

Metabolomics as a Tool in Nutrition Research. Elsevier. 2015. ISBN: 978-1-78242-084-2

学术兼职

World Journal of Diabetes，编委

BMC Medicine，编委

Journal of Translational Gastroenterology，编委

Frontiers in Pharmacology – Translational Pharmacology, 副主编

Frontiers in Pharmacology-Experimental Pharmacology and Drug Discovery, 副主编

深圳市分析测试协会医学测试专业委员会常务委员

广东省科学技术厅项目评审专家

深圳市科技创新委员会科技专家

广东省精准医学应用学会微生态医学分会委员